England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

Clinical outcomes from routine practice confirm ocrelizumab effectiveness in relapsing MS, with low rates of disability worsening over 4 years.

Nearly 90% of patients with relapsing-remitting MS in a multicenter study in Germany preferred subcutaneous administration of Tysabri rather than IV, citing shorter duration of delivery and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Results from the EVOLVE-MS-1 study show ...

"Our findings prompt the inevitable question of whether the current phenotype classification of relapse-onset MS into relapsing-remitting and secondary progressive MS is as useful as we thought, for ...

The novel drug vidofludimus calcium (Immunic Therapeutics) is safe and effective for patients with relapsing-remitting multiple sclerosis (RRMS), new research suggests. Vidofludimus calcium is an ...

An agent biologically similar to the humanized monoclonal antibody natalizumab is as effective and safe as the original reference drug for relapsing-remitting multiple sclerosis (RRMS) — and has a ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Multiple ...

Two new sub-types of multiple sclerosis (MS) were discovered by researchers from Queen Square Analytics and University ...

A stem cell treatment commonly used for blood cancer appears effective in treating one form of MS The treatment has been available since the 1990s but questions about safety and difficulty have ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...